Atea Pharmaceuticals Initiates First-in-Human Phase I Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus

Atea Pharmaceuticals, Inc. announced the initiation of a first-in-human Phase I clinical trial evaluating AT-587, for the treatment of hepatitis E virus infection.